BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
Hunt Anthony reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Anthony Hunt received a grant of 8,170 shares of common stock as a restricted stock award. The award was made at no cash cost per share and increased his directly held common stock to 15,046 shares following the transaction. According to the footnote, the restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and "fully vests on the first anniversary of the vesting date of January 2, 2026."
Coste Catherine reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Catherine Coste reported an equity award of 8,170 shares of common stock as a grant under the BioLife Solutions 2023 Performance Incentive Plan. The restricted stock was granted at no cash price and will fully vest on the first anniversary of the vesting date of January 2, 2026. Following this award, Coste beneficially owns 13,871 common shares directly.
Ellingson Rachel reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Rachel Ellingson reported receiving a grant of 8,170 shares of restricted common stock. The award was recorded at a price of $0.00 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
These shares were granted under the BioLife Solutions 2023 Performance Incentive Plan and, according to the terms, fully vest on the first anniversary of the vesting date of January 2, 2026. Following this grant, Ellingson directly holds a total of 57,995 shares of BioLife Solutions common stock.
BioLife Solutions President and CEO Roderick De Greef reported several equity awards and related tax withholdings. On February 24, 2026, he acquired three blocks of restricted common stock totaling 118,730, 170,291 and 219,024 shares at a stated price of $0.00 per share.
The awards were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan, including 2026 compensation that vests 25% on the first anniversary and then in 12 equal quarterly installments. Other restricted stock vested based on total shareholder return from January 1, 2024 to December 31, 2025 versus peers and on specific performance metrics, leading to vesting at approximately 156% and 200% of target.
To satisfy tax withholding obligations on the market‑ and performance‑based vesting, 67,010 and 86,186 shares were disposed of at $22.65 per share through share withholding rather than open‑market sales. After these transactions, De Greef directly held 744,847 shares of BioLife Solutions common stock.
BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, reported equity awards and related share withholding in company stock. He acquired 20,096 shares of restricted common stock and 39,605 shares of market-based restricted stock on February 24, 2026 at a stated price of $0.0000 per share.
The awards were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan as part of 2026 compensation. One grant vests 25% on the first anniversary of the grant date and then in 12 equal quarterly installments. The market-based award vested at approximately 156% of the original grant based on relative total shareholder return versus selected peers from January 1, 2024 through December 31, 2025.
To cover tax withholding obligations on the vesting of the market-based award, 15,585 shares were withheld at $22.65 per share. Following these transactions, Mathew Aby J. directly owns 393,466 shares of BioLife Solutions common stock.
BioLife Solutions Chief Human Resources Officer Sarah Aebersold received a grant of 23,548 shares of common stock at $0.00 per share, tied to the company’s 2023 Omnibus Performance Incentive Plan. About 156% of the target shares vested based on relative total shareholder return, and 5,734 shares were withheld at $22.65 per share to cover taxes, leaving her with 93,579 shares directly owned.
Werner Sean reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Chief Technology Officer Sean Werner received a grant of 24,116 shares of common stock as part of his 2026 compensation. The restricted stock was issued under the 2023 Omnibus Performance Incentive Plan and will vest 25% on the first anniversary of the grant date, then in 12 equal quarterly installments. Following this award, he directly holds 50,043 shares of common stock.
MOORE TIMOTHY L. reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions director Timothy L. Moore received a grant of 8,170 shares of restricted common stock. The award was made at a stated price of $0.0000 per share and was granted under the BioLife Solutions 2023 Performance Incentive Plan.
According to the filing, these restricted shares will fully vest on the first anniversary of the vesting date of January 2, 2026. After this grant, Moore directly holds a total of 44,943 shares of BioLife Solutions common stock.
BioLife Solutions executive Karen A. Foster reported equity compensation activity involving company common stock. She acquired 32,112 shares at no cost as a grant under the BioLife Solutions 2023 Omnibus Performance Incentive Plan. The restricted stock vested at approximately 156% of the target amount based on total shareholder return versus selected peers for the period from January 1, 2024 through December 31, 2025. In a related tax-withholding disposition, 13,013 shares were withheld at a price of $22.65 per share to cover tax obligations upon vesting. After these transactions, she directly held 211,083 shares of common stock.
GOSWAMI JOYDEEP reported acquisition or exercise transactions in this Form 4 filing.
BioLife Solutions Inc. director Joydeep Goswami received a grant of 8,170 shares of restricted common stock, recorded at a price of $0 per share as a stock award rather than a market purchase. Following this grant, his directly held common stock increased to 53,156 shares.
The restricted stock was granted under the BioLife Solutions 2023 Performance Incentive Plan and, according to the disclosure, will fully vest on the first anniversary of the vesting date of January 2, 2026.